ORG 25435

Drug Profile

ORG 25435

Latest Information Update: 06 Dec 2007

Price : $50

At a glance

  • Originator Organon
  • Class General anaesthetics; Phenols; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anaesthesia

Most Recent Events

  • 06 Dec 2007 Discontinued - Phase-I for Anaesthesia in United Kingdom (IV)
  • 13 Mar 2001 A study has been added to the pharmacodynamics and adverse events sections
  • 07 Mar 2001 Phase-I clinical trials for Anaesthesia in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top